指南与共识神经肿瘤

颅内非海绵窦良性脑膜瘤的立体定向放射外科治疗:ISRS系统综述、荟萃分析及实践指南

Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline.
指南 / 共识 · Neurosurgery · 2020-01-01

10年局部控制率为71%–100%,10年无进展生存率为55%–97%,处方剂量通常为单次12–15 Gy,毒性率普遍较低。推荐SRS可作为1级脑膜瘤的有效循证治疗选择(推荐级别II)。

要点

  • SRS可作为1级颅内非海绵窦良性脑膜瘤的有效循证治疗选择(推荐级别II)。
  • 10年局部控制率71%–100%,10年无进展生存率55%–97%。
  • 处方剂量通常为单次12–15 Gy,毒性率普遍较低。

核心结论

  • 现有支持SRS治疗良性颅内脑膜瘤的文献缺乏I级和II级证据,但汇总大量III级研究后,SRS可被推荐为1级脑膜瘤的有效循证治疗选择(推荐级别II)。

研究设计与样本

  • ISRS按系统综述方法检索PubMed、EMBASE和Cochrane Central Register三个电子数据库,纳入1964年1月至2018年4月发表的英文SRS治疗良性颅内脑膜瘤文献。
  • 共识别2844项研究,305项进行全文评估,最终27项研究符合纳入标准;除1项外均为回顾性研究。

主要发现

  • 10年局部控制率范围为71%–100%。
  • 10年无进展生存率范围为55%–97%。
  • 处方剂量通常为单次12–15 Gy。
  • 毒性率普遍较低。

关键数值与推荐

  • 推荐SRS作为1级脑膜瘤的有效循证治疗选择,推荐级别II。
  • 典型处方剂量为单次12–15 Gy。

临床怎么用

  • 对1级颅内非海绵窦良性脑膜瘤,可将SRS作为有效治疗选择进行个体化推荐。
  • 处方剂量可参考单次12–15 Gy的典型范围。

局限性

  • 现有文献缺乏I级和II级证据。
  • 纳入的27项研究中除1项外均为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiosurgery (SRS) for benign intracranial meningiomas is an established treatment. OBJECTIVE: To summarize the literature and provide evidence-based practice guidelines on behalf of the International Stereotactic Radiosurgery Society (ISRS). METHODS: Articles in English specific to SRS for benign intracranial meningioma, published from January 1964 to April 2018, were systematically reviewed. Three electronic databases, PubMed, EMBASE, and the Cochrane Central Register, were searched. RESULTS: Out of the 2844 studies identified, 305 had a full text evaluation and 27 studies met the criteria to be included in this analysis. All but one were retrospective studies. The 10-yr local control (LC) rate ranged from 71% to 100%. The 10-yr progression-free-survival rate ranged from 55% to 97%. The prescription dose ranged typically between 12 and 15 Gy, delivered in a single fraction. Toxicity rate was generally low. CONCLUSION: The current literature supporting SRS for benign intracranial meningioma lacks level I and II evidence. However, when summarizing the large number of level III studies, it is clear that SRS can be recommended as an effective evidence-based treatment option (recommendation level II) for grade 1 meningioma.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Marchetti M, Sahgal A, De Salles AAF, et al. Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline. Neurosurgery. 2020. PMID: 32463867. doi:10.1093/neuros/nyaa169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。